Categories: News

Accelerate Diagnostics to Participate in William Blair 41st Annual Growth Stock Conference on June 3, 2021

TUCSON, Ariz., May 19, 2021 /PRNewswire/ — Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that Chief Executive Officer, Jack Phillips, and Chief Financial Officer, Steve Reichling, will present virtually at the William Blair 41st Annual Growth Stock Conference on Thursday, June 3, 2021 at 12:00 p.m. Central Time.

A live audiocast of the session will be accessible through the company’s investor relations website at ir.axdx.com. A replay of the audiocast will be available for at least 30 days following the conference.

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for serious infections. The FDA-cleared system and kit fully automate sample preparation steps, enabling phenotypic antibiotic susceptibility results in about 7 hours directly from positive blood cultures. Recent external studies indicate the solution offers results 1 to 2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient’s infection, days earlier.

The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and “ACCELERATE PHENOTEST” and diamond shaped logos and marks are registered trademarks of Accelerate Diagnostics, Inc.

For more information about the company, its products and technology, or recent publications, visit axdx.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/accelerate-diagnostics-to-participate-in-william-blair-41st-annual-growth-stock-conference-on-june-3-2021-301294554.html

SOURCE Accelerate Diagnostics, Inc.

Staff

Recent Posts

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

4 hours ago

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…

7 hours ago

Nutri Derma Guard Skin Tag Remover Ingredients Investigated: 2026 Analysis Examines Formulation And Consumer Disclosures

Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…

7 hours ago

SleepZee Mouth Guard Legitimacy Examined: 2026 Consumer Analysis Investigates Anti-Snoring Device Claims and Company Transparency

Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…

7 hours ago